Fora Capital, LLC Editas Medicine, Inc. Transaction History

Fora Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$31.29 - $56.64 $224,098 - $405,655	-7,162 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $284,403 - $648,733	7,162 New	7,162 $301 Million
Q3 2020 Nov 13, 2020	SELL	$28.06 - $37.16 $267,215 - $353,874	-9,523 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$18.5 - $34.34 $136,456 - $253,291	7,376 Added 343.55%	9,523 $282 Million
Q1 2020 May 15, 2020	SELL	$14.88 - $32.78 $98,103 - $216,118	-6,593 Reduced 75.43%	2,147 $42,000
Q4 2019 Feb 14, 2020	BUY	$19.49 - $32.63 $170,342 - $285,186	8,740 New	8,740 $258,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Fora Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Fora Capital, LLC with notifications on news.